Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
Center for the Treatment of Obesity and Diabetes, Hospital Oswaldo Cruz, Sao Paulo, Brasil.
Ann Med. 2023 Dec;55(1):2203517. doi: 10.1080/07853890.2023.2203517.
Obesity is a chronic disease characterised by excess adiposity, which impairs health. The high prevalence of obesity raises the risk of long-term medical complications including type 2 diabetes and chronic kidney disease. Several studies have focused on patients with obesity, type 2 diabetes and chronic kidney disease due to the increased prevalence of diabetic kidney disease. Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease showed renoprotective effects. However, further research is critical to address the treatment of patients with obesity and chronic kidney disease to lessen morbidity.Key messageObesity is a driver of chronic kidney disease, and type 2 diabetes, along with obesity, accelerates chronic kidney disease.Several randomized controlled trials on sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 analogues, and bariatric surgery in diabetic kidney disease demonstrate the improvement of renal outcomes.There is a need to address the treatment of patients with obesity and CKD to lessen morbidity.
肥胖是一种以脂肪过多为特征的慢性疾病，会损害健康。肥胖的高发率增加了长期医疗并发症的风险，包括 2 型糖尿病和慢性肾脏病。由于糖尿病肾病的发病率增加，一些研究集中在肥胖、2 型糖尿病和慢性肾脏病患者身上。几项关于钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 类似物和减肥手术在糖尿病肾病中的随机对照试验显示了肾脏保护作用。然而，为了减少发病率，解决肥胖和慢性肾脏病患者的治疗问题至关重要。
关键信息
肥胖是慢性肾脏病的驱动因素，2 型糖尿病与肥胖一起加速慢性肾脏病的发展。
几项关于钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 类似物和减肥手术在糖尿病肾病中的随机对照试验表明，肾脏结局得到了改善。
需要解决肥胖和 CKD 患者的治疗问题，以降低发病率。
